Further Information
SLAM family member 7, CD2 subset 1, CD2-like receptor-activating cytotoxic cells, CRACC, Membrane protein FOAP-12, Novel Ly9, Protein 19A, CD319, SLAMF7, CS1
For WB starting dilution is: 1:1000
SLAMF7 contains one Ig-like C2-type (immunoglobulin-like) domain. Isoform 1 mediates NK cell activation through a SAP-independent extracellular signal-regulated ERK-mediated pathway. It may play a role in lymphocyte adhesion. Isoform 3 does not mediate any activation. SAP can bind the cytoplasmic tail of isoform 1 when phosphorylated in the presence of Fyn (in vitro). SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Expression was detected in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-, or T-cell lines. The isoform 3 is expressed at much lower level than isoform 1. There are three named isoforms.
- Tovar, V., et al. Immunogenetics 54(6):394-402(2002)
- Murphy, J.J., et al. Biochem. J. 361 (PT 3), 431-436 (2002)
- Bouchon, A., et al. J. Immunol. 167(10):5517-5521(2001)
- Boles, K.S., et al. Immunogenetics 52 (3-4), 302-307 (2001)
Supplied in PBS with 0.09% (W/V) sodium azide.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
This SLAMF7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 58-85 amino acids from the Central region of human SLAMF7.
57823
SLAM family member 7
SLAMF7
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
37 kDa
Q9NQ25
66774034
This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunology
Q9NQ25
Optimal dilutions for each application to be determined by the researcher.